PPBTPURPLE BIOTECH LTD.

Nasdaq purple-biotech.com


$ 0.46 $ 0.02 (3.9 %)    

Friday, 06-Sep-2024 09:52:22 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 0.4505
-- x --
-- x --
-- - --
$ 0.30 - $ 1.80
91,920
na
11.37M
$ 1.11
$ 1.06
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-purple-biotech-lowers-price-target-to-8

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target f...

 purple-biotech-q2-eps-009-beats-012-estimate

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 why-purple-biotech-ppbt-shares-are-trading-lower

Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants fo...

 purple-biotech-exercises-warrants-for-2m-gross-proceeds

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developin...

 reported-saturday-purple-biotech-revealed-results-from-a-phase-2-study-at-asco-2024-showing-cm24-improved-overall-survival-and-other-efficacy-endpoints-in-pancreatic-cancer

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patie...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-q1-2024-gaap-epads-014-beats-015-estimate-cash-9985m

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION